Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 May;37(5):1088-1093.
doi: 10.1002/mds.28970. Epub 2022 Feb 26.

A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease

Olivier Rascol  1 , Rossella Medori  2 , Corine Baayen  3 , Pedro Such  3 , Didier Meulien  3 ; AMBLED Study Group
Affiliations
Clinical Trial

A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease

Olivier Rascol et al. Mov Disord. 2022 May.

Abstract

Background: Agents targeting the metabotropic glutamate receptor 4 have emerged as a potentially attractive new class of drugs for the treatment of Parkinson's disease (PD).

Objective: The objective of this study was to evaluate the efficacy and safety of foliglurax in reducing off time and dyskinesia in patients with PD.

Methods: This was a 28-day, multicenter, randomized, placebo-controlled, double-blind clinical trial of foliglurax 10 and 30 mg as adjunct to levodopa in 157 randomly assigned patients with PD and motor complications.

Results: Although dose-dependent decreases in daily awake off time were apparent following treatment with foliglurax, the change from baseline to day 28 in off time (primary endpoint) and dyskinesia (secondary endpoint) did not improve significantly compared with placebo for either foliglurax dose. Treatment with foliglurax was generally safe, and there were no relevant safety signals.

Conclusions: There was no evidence in this study that foliglurax has efficacy in improving levodopa-induced motor complications in PD. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keywords: Parkinson's disease; dyskinesia; foliglurax; mGlu4 receptor; positive allosteric modulator.

PubMed Disclaimer

References

    1. Aquino CC, Fox SH. Clinical spectrum of levodopa‐induced complications. Mov Disord 2015;30(1):80–89. - PubMed
    1. Hametner E, Seppi K, Poewe W. The clinical spectrum of levodopa‐induced motor complications. J Neurol 2010;257(Suppl 2):S268–S275. - PubMed
    1. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006;63(12):1756–1760. - PubMed
    1. Olanow CW, Kieburtz K, Rascol O, et al. Factors predictive of the development of levodopa‐induced dyskinesia and wearing‐off in Parkinson's disease. Mov Disord 2013;28(8):1064–1071. - PubMed
    1. Kadastik‐Eerme L, Taba N, Asser T, Taba P. Factors associated with motor complications in Parkinson's disease. Brain Behav 2017;7(10):e00837 - PMC - PubMed

Publication types

LinkOut - more resources